Baidu
map

数字化营销迎来全新变革,梅斯医学加速数字营销布局

2021-10-19 JACKZHAO MedSci原创

作为精准数字化医学传播解决方案领导者,梅斯医学参与其中,包括梅斯医学董事长张发宝及梅斯医学副总经理、APO负责人孙超均受邀参加此次会议,并带来了关于数字化营销主题分享和医疗端变化与未来策略的圆桌讨论。

2021香山汇暨中国药品流通社会物流年会

10月18-19日,2021香山汇暨中国药品流通社会物流年会在北京举行。

“香山汇”由中国医药商业协会旗下权威期刊《中国药品流通》杂志主办,旨在汇聚医药行业工业与商业同道力量和智慧,推动医药商务工作不断创新探索,促进药品流通行业持续健康发展。“香山汇”越来越成为医疗行业热点会议,来自政府、行业专家、企事业等百家机构与单位,近300人参加了此次会议。 

医药产业舞台正拉开下一幕的临界点上,在包括带量集采、医院准入、医疗数字营销、支付创新、双通道、供应链创新、药物可及等等医药商务工作的热门话题上,此次香山汇跳出了行业的视域,在更高的视角去凝望未来,去仔细观察推动我们进化的背后大逻辑,去关注那些足以深刻影响我们未来的细节和创新。

作为精准数字化医学传播解决方案领导者,梅斯医学参与其中,包括梅斯医学董事长张发宝及梅斯医学副总经理、APO负责人孙超受邀参加此次会议,并带来关于数字化营销主题分享和医疗端变化与未来策略圆桌讨论。

梅斯医学副总经理、APO负责人孙超

梅斯医学副总经理、APO负责人孙超在题为“数字化营销的协同性”主题发言中表示,未来医疗数字化浪潮已是大势所趋,要尽快入局,加紧布局。

孙超解释道,近年来,政府逐步放开并鼓励互联网+医疗发展,从最初的谨慎探索到2020年的明确指导和实施方案,目前已发布30多项数字化医疗相关政策和90多项互联网医疗相关政策,这为数字化医疗服务的发展提供了有力政策支持。从医疗服务端而言,医院和医生均分别广泛参与互联网医院和数字医疗平台,目前已成立超1600家互联网医院,有超百万的医生参与线上平台当中。而疫情催生下,医患及企业端的数字化医疗需求更是被突飞猛进的被激活。

梅斯医学近20年在医药数字化领域探索

梅斯医学是医药数字化的早期入局者,近20年在医药数字化领域不断探索布局,并取得诸多成果,已经成长成为成为领先的数字化临床研究和医学学术传播平台。给国内外上百家知名的药企和器械公司提供医疗数字营销解决方案

目前,梅斯医学拥有梅斯医学与生物谷两大平台,全网日均总PV超100万,注册医生会员已超340万,覆盖全国省、自治区和直辖市达510个城市。其中,一、二线城市会员用户占比达43%。专注临床研究与临床知识传播,高职称活跃用户占行业首位,2016年独角兽工作室医学类网站排名第二,用户专业度排名第一。

梅斯会员概况,数据来源:medsci.cn 统计时间:2021年05月

就在近期,梅斯医学凭借专业的数字化医学服务,荣获2021中国数字医疗企业百强榜医药数字化企业TOP10该榜单是由亿欧智库、亿欧大健康历时数月评选“2021年中国大健康产业集成创新榜单”。

梅斯医学以其独特学术科研支持体系为引擎,极大助力药企的循证挖掘与学术传播推广。孙超特别强调梅斯医学基于梅斯优势资源在数字化学术推广方面,可以针对不同维度的产品,梅斯医学APOAcademic Promotion Organization学术传播服务)可以提供定制化的解决方案组合,实现协同共赢。

APO基于企业原有架构提供数字化的解决方案

孙超以梅斯医学此前为客户提供的整合型数字化解决方案为例阐述梅斯数字化策略,该案例通过精准匹配、学术产出运营、线上线下协同的方式,打造虚拟代表、微信社群和SST三大策略,医院/医生覆盖规模显著提升,并完成17家进列名进院共同完成业务转化,成功拓展下沉市场造福广大患者。

总之,梅斯医学能够提供基于产品不同生命周期的数字化医学服务和数字营销服务,致力于服务合规、专业学术赋能、数字化降本增效,协同赋能,实现合作共赢。

医疗端变化与未来策略的圆桌讨论

梅斯医学董事长张发宝博士在医疗端变化与未来策略的圆桌讨论中表示,梅斯医学的数字化营销与真实世界研究两块业务,事实上二者是一脉相承的真实世界研究为药械提供医学证据,而数字化营销将这些证据传播给目标医生。

在张发宝博士看来,数字化营销虽然提20年了,但他认为在2020年以前一直是一个摆设噱头的概念,只是一个工具(e-tool)而已。自2020年后,从政策的改变、疫情等多因素影响后这一观点发生改变,数字化营销迎来全新变革,数字化营销与传统营销走向融合。未来数字化营销能够真正帮助产品触达最后一公里,拉近企业产品与医生和患者的距离,医药与互联网的产业融合也将更加紧密。

对于数字化营销未来,张发宝博士表示,从2021到2022,再到2023年的数字化大趋势肯定是不会变的,中间可能会有起起伏伏、小的波澜,但只是走的快一点或者慢一点以及怎么走的问题而已。数字化在未来一段时间内都是很好的高速成长机会,梅斯医学希望与合作伙伴一道能够在这快速变革医药商业环境中能够获得更好的站位与机会。

据了解,梅斯医学未来将重点着力打造梅斯医学APO学术服务能力,不断提升精准筛选高价值客户能力,设计输出高质量医学内容、将构建全新的内容分发平台,采用DMC+SCRM数字化通路高效低成本传递医学信息,持续提升精准触达能力,另外也将解决企业评估学术服务效果的难题。与此同时,梅斯医学自身也将注重在医生端和患者端上同时进行布局,真正提升临床医疗服务质量,这也是梅斯医学的使命。

我们认为未来医疗数字化将进一步深化,数字化营销的概念边界仍将获得不断突破,会不断涌现出全新的模式与技术。后疫情时代,数字营销正在成为药企主要阵地,也正在影响整个医疗服务链条,包括与医疗保险、个性化医疗服务、疾病健康管理等等。

 

------

关于梅斯医学

 

梅斯医学( MedSci )是面向医生的综合互联网平台,应用大数据和人工智能技术链接医生、患者、药械企业等,提供精准数字化医学传播解决方案,优化医疗生态,改善医疗质量,共创美好健康生活。

梅斯医学主要产品包括数字化医学传播和数字化临床研究,涵盖临床研究、医生职业成长、多渠道学术传播、智慧医疗等类别。在数字化临床研究层面,提供临床研究整体解决方案,通过数字化技术降低成推本,提升质量;在数字化医学传播方面,提供数字化的专业医学内容和精准、整合的传播方案,将最新的技术与知识精准地传递给目标医生。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1277276, encodeId=8c3512e72763c, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Oct 21 13:33:50 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363496, encodeId=671f136349613, content=<a href='/topic/show?id=46135e6658f' target=_blank style='color:#2F92EE;'>#数字化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57665, encryptionId=46135e6658f, topicName=数字化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e05e201, createdName=appleandpeer, createdTime=Thu Oct 21 13:33:50 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062196, encodeId=04a11062196a3, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/QrJHibZuZNzgOStgCMjwJGuVoxWicdPQyahiaXJk2JIkMTYKqdZTAuwQ5ldicWovZ19ia4icPjPicLpEaJtTIGrXuWXJA/132, createdBy=38fa5329475, createdName=宋, createdTime=Wed Oct 20 09:58:33 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062155, encodeId=54e010621554c, content=!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d3a4700555, createdName=595690844, createdTime=Wed Oct 20 07:27:18 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062147, encodeId=2b79106214e9a, content=不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Wed Oct 20 06:50:18 CST 2021, time=2021-10-20, status=1, ipAttribution=)]
    2021-10-21 一闲
  2. [GetPortalCommentsPageByObjectIdResponse(id=1277276, encodeId=8c3512e72763c, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Oct 21 13:33:50 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363496, encodeId=671f136349613, content=<a href='/topic/show?id=46135e6658f' target=_blank style='color:#2F92EE;'>#数字化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57665, encryptionId=46135e6658f, topicName=数字化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e05e201, createdName=appleandpeer, createdTime=Thu Oct 21 13:33:50 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062196, encodeId=04a11062196a3, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/QrJHibZuZNzgOStgCMjwJGuVoxWicdPQyahiaXJk2JIkMTYKqdZTAuwQ5ldicWovZ19ia4icPjPicLpEaJtTIGrXuWXJA/132, createdBy=38fa5329475, createdName=宋, createdTime=Wed Oct 20 09:58:33 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062155, encodeId=54e010621554c, content=!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d3a4700555, createdName=595690844, createdTime=Wed Oct 20 07:27:18 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062147, encodeId=2b79106214e9a, content=不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Wed Oct 20 06:50:18 CST 2021, time=2021-10-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1277276, encodeId=8c3512e72763c, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Oct 21 13:33:50 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363496, encodeId=671f136349613, content=<a href='/topic/show?id=46135e6658f' target=_blank style='color:#2F92EE;'>#数字化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57665, encryptionId=46135e6658f, topicName=数字化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e05e201, createdName=appleandpeer, createdTime=Thu Oct 21 13:33:50 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062196, encodeId=04a11062196a3, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/QrJHibZuZNzgOStgCMjwJGuVoxWicdPQyahiaXJk2JIkMTYKqdZTAuwQ5ldicWovZ19ia4icPjPicLpEaJtTIGrXuWXJA/132, createdBy=38fa5329475, createdName=宋, createdTime=Wed Oct 20 09:58:33 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062155, encodeId=54e010621554c, content=!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d3a4700555, createdName=595690844, createdTime=Wed Oct 20 07:27:18 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062147, encodeId=2b79106214e9a, content=不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Wed Oct 20 06:50:18 CST 2021, time=2021-10-20, status=1, ipAttribution=)]
    2021-10-20

    支持

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1277276, encodeId=8c3512e72763c, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Oct 21 13:33:50 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363496, encodeId=671f136349613, content=<a href='/topic/show?id=46135e6658f' target=_blank style='color:#2F92EE;'>#数字化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57665, encryptionId=46135e6658f, topicName=数字化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e05e201, createdName=appleandpeer, createdTime=Thu Oct 21 13:33:50 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062196, encodeId=04a11062196a3, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/QrJHibZuZNzgOStgCMjwJGuVoxWicdPQyahiaXJk2JIkMTYKqdZTAuwQ5ldicWovZ19ia4icPjPicLpEaJtTIGrXuWXJA/132, createdBy=38fa5329475, createdName=宋, createdTime=Wed Oct 20 09:58:33 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062155, encodeId=54e010621554c, content=!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d3a4700555, createdName=595690844, createdTime=Wed Oct 20 07:27:18 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062147, encodeId=2b79106214e9a, content=不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Wed Oct 20 06:50:18 CST 2021, time=2021-10-20, status=1, ipAttribution=)]
    2021-10-20 595690844

    !!!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1277276, encodeId=8c3512e72763c, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Oct 21 13:33:50 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363496, encodeId=671f136349613, content=<a href='/topic/show?id=46135e6658f' target=_blank style='color:#2F92EE;'>#数字化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57665, encryptionId=46135e6658f, topicName=数字化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e05e201, createdName=appleandpeer, createdTime=Thu Oct 21 13:33:50 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062196, encodeId=04a11062196a3, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/QrJHibZuZNzgOStgCMjwJGuVoxWicdPQyahiaXJk2JIkMTYKqdZTAuwQ5ldicWovZ19ia4icPjPicLpEaJtTIGrXuWXJA/132, createdBy=38fa5329475, createdName=宋, createdTime=Wed Oct 20 09:58:33 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062155, encodeId=54e010621554c, content=!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d3a4700555, createdName=595690844, createdTime=Wed Oct 20 07:27:18 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062147, encodeId=2b79106214e9a, content=不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Wed Oct 20 06:50:18 CST 2021, time=2021-10-20, status=1, ipAttribution=)]
    2021-10-20 仁术2021

    不错学习了

    0

相关资讯

2021首届医学数字营销峰会议程出炉!

导语| 聚焦医学创新,助力数字营销!首届医学数字营销峰会期待您的参与!

Baidu
map
Baidu
map
Baidu
map